| Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late | | |
| Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage | European Medical Journal Innovations | 2021 |
| Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment | Drugs in R and D | 2021 |
| Experimental Pharmacotherapy for COVID-19: The Latest Advances | Journal of Experimental Pharmacology | 2021 |
| Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia | Frontiers in Immunology | 2021 |
| SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19 | PLoS Computational Biology | 2021 |
| Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements | 3 Biotech | 2021 |
| Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review | Journal of Inflammation Research | 2021 |
| Potential role of subcutaneous tocilizumab injections in patients with COVID-19 associated pneumonia | Journal of Medical Virology | 2021 |
| Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia | International Journal of Infectious Diseases | 2021 |
| Repurposed Tocilizumab in Patients with Severe COVID-19 | Journal of Immunology | 2021 |
| COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia | Clinical Pharmacology and Therapeutics | 2021 |
| Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement | Annals of the Rheumatic Diseases | 2021 |
| Current pharmacological treatments for COVID-19: What's next? | British Journal of Pharmacology | 2020 |
| Translating IL-6 biology into effective treatments | Nature Reviews Rheumatology | 2020 |
| The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic | Nature Reviews Rheumatology | 2020 |
| A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome | Journal of Clinical Pharmacology | 2020 |
| Consider Adjunctive Ketamine in Mechanically Ventilated Coronavirus Disease-2019 Patients | Journal of Cardiothoracic and Vascular Anesthesia | 2020 |
| IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? | Pharmaceutical Medicine | 2020 |
| Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19 | Clinical Pharmacology and Therapeutics | 2020 |
| Pharmacological treatments of COVID-19 | Pharmacological Reports | 2020 |
| Knowledge, Attitudes, and Practice Regarding COVID-19 among Patients with Musculoskeletal and Rheumatic Diseases in Nepal: A Web-Based Cross-Sectional Study | Open Access Rheumatology: Research and Reviews | 2020 |
| Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature | Drugs and Therapy Perspectives | 2020 |
| Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab | Indian Pediatrics | 2020 |
| Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework | Statistics in Biopharmaceutical Research | 2020 |
| Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? | BMC Medicine | 2020 |
| Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19 | Frontiers in Public Health | 2020 |
| Outlook of IL-6 signaling blockade for COVID-19 pneumonia | Inflammation and Regeneration | 2020 |
